Jinwon Life Sciences Subsidiary VGXI Approved as Member of US BioMap Consortium
Jinwon Life Sciences announced on the 21st that its subsidiary VGXI, a leading contract development and manufacturing organization (CDMO) in the field of nucleic acid biopharmaceuticals such as gene therapy, DNA vaccines, and RNA drugs, has been approved as a member of the US BioMap consortium.
The company explained that the BioMap consortium aims to strengthen the capabilities of the US bio industry and expand the production volume of biopharmaceuticals, with the purpose of providing necessary funding support, improving supply chain flexibility, and securing medical supplies for public health.
With this approval as a member of the BioMap consortium, VGXI plans to contribute to public health through biopharmaceutical production and related material development alongside more than 200 member companies, leveraging its experience in plasmid DNA production and a 4000L plasmid DNA production capacity.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
Youngkeun Park, CEO of Jinwon Life Sciences, said, “Following our selection as a member of the Rapid Response Partnership Vessel (RRPV) supported by the Biomedical Advanced Research and Development Authority (BARDA) under the US Department of Health and Human Services, becoming a member of the BioMap consortium allows us to expect an increase in our plasmid DNA supply necessary to respond to public health threats.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
